Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Total Non-Current Liabilities of $831000.0 for Q1 2026, down 64.15% year-over-year from $2.3 million in Q1 2025, and down 11.12% quarter-over-quarter from $935000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Total Non-Current Liabilities for 11 consecutive years, with $831000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 64.15% year-over-year to $831000.0; the TTM figure through Mar 2026 stood at $831000.0 (down 64.15% YoY), while the FY2025 annual figure was $935000.0, down 45.35% from the prior year.
- Total Non-Current Liabilities retreated to $831000.0 in Q1 2026 per SLGL's latest filing, from $935000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.5 million in Q2 2025 and bottomed at $831000.0 in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $1.7 million across 5 years, with a median of $1.7 million in 2022.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 95.3% — and 2026, when it tumbled 64.15%.
- Sol-Gel Technologies' Total Non-Current Liabilities stood at $1.1 million in 2022, then surged by 95.3% to $2.1 million in 2023, then declined by 19.33% to $1.7 million in 2024, then slumped by 45.35% to $935000.0 in 2025, then slipped by 11.12% to $831000.0 in 2026.
- Business Quant data shows SLGL's Total Non-Current Liabilities at $831000.0 in Q1 2026, $935000.0 in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 831,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 831,000.00 |
| Dec 31, 2025 | 935,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.00 Mn |